Pfizer Reports Strong Third-Quarter 2026 Results And Raises 2026 Guidance

What happened

Pfizer reported third-quarter 2026 revenues of $16.6 billion, relatively flat year-over-year operationally. Excluding its Comirnaty and Paxlovid products, revenue grew, and Pfizer raised its full-year 2026 guidance for both revenues and adjusted diluted earnings per share.

Confirmed

Global impact / market context

Raising guidance signals management expects stronger results ahead than previously planned. Non-COVID products growing 7% shows Pfizer's sales base is broadening beyond pandemic-era products. Launched and acquired products growing 32% suggests newer medicines are becoming a larger part of revenue, which matters for profit durability.

Analyst inference

Investors often treat raised guidance as a confidence signal for future earnings. Flat total revenue alongside growth excluding COVID products points to a business mix shift rather than simple expansion. How investors weigh that shift will shape expectations for Pfizer's stock.

Analyst inference

What to watch

1. Watch whether Pfizer meets the raised full-year 2026 guidance for revenues and adjusted diluted earnings per share, which is earnings per share excluding certain items. Confirmed
2. Watch progress in Pfizer's obesity program and its pipeline milestones in oncology, immunology and vaccines, which leadership cited as catalysts ahead. Proposed
3. Watch whether launched and acquired products keep growing near 32% and whether non-COVID products sustain 7% growth, which would support the raised guidance. Analyst inference

Evidence

• Original source link unavailable